Therapeutic options for Acinetobacter baumannii infections.
about
Crystal Structure of Hcp from Acinetobacter baumannii: A Component of the Type VI Secretion SystemComparative proteomics of inner membrane fraction from carbapenem-resistant Acinetobacter baumannii with a reference strainPhosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system.Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection.Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.Acinetobacter baumannii Septicemia in a Recipient of an Allogeneic Hematopoietic Stem Cell Transplantation.In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.Xuebijing Protects Rats from Sepsis Challenged with Acinetobacter baumannii by Promoting Annexin A1 Expression and Inhibiting Proinflammatory Cytokines Secretion.Multidrug-resistant Gram-negative infections: the use of colistin.Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models.Therapeutic options for Acinetobacter baumannii infections: an update.Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii.Activity of Gallium Meso- and Protoporphyrin IX against Biofilms of Multidrug-Resistant Acinetobacter baumannii Isolates.The outer membrane porin OmpW of Acinetobacter baumannii is involved in iron uptake and colistin binding.Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection.Co-production of ESBL and AmpC β-Lactamases in Clinical Isolates of A. baumannii and A. lwoffii in a Tertiary Care Hospital From Northern India.Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.Rapid detection of antibiotic resistance in Acinetobacter baumannii using quantitative real-time PCR.CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.Extended spectrum and metalo beta-lactamase producing airborne Pseudomonas aeruginosa and Acinetobacter baumanii in restricted settings of a referral hospital: a neglected condition.In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.Pharmacophore generation of 2-substituted benzothiazoles as AdeABC efflux pump inhibitors in A. baumannii.Molecular epidemiology and mechanism of sulbactam resistance in Acinetobacter baumannii isolates with diverse genetic background in China.Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumanniiTigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: Susceptibility and clinical outcomeAntimicrobial Survey of Local Herbal Drugs against Isolated from Patients Admitted to a Level-I Trauma Center
P2860
Q30152905-23EFD2AE-93D1-49F5-861C-2585C15AC71CQ31071263-AD9D3C7D-4CA1-4666-B40F-7FA27156CAE1Q33901939-B085C0A1-87A0-4DF3-B155-E6BA105A67DAQ34484474-ADB4CE74-3C1D-4B64-90CC-5AC8AFCCB6A4Q34653632-1BFBAF02-3EBE-40A7-B6D4-EAE3874EFAC7Q35222421-CC23212F-C887-4FFD-84FF-43DB2A0B19A3Q36417501-43464068-F7A7-4D6D-8861-0B9AC668E0F6Q37392820-3C4A7572-1ED0-43F3-93AF-C4A6F2624E37Q37393081-63F1C7BE-3D30-4CBF-89D5-04AE39E73325Q37785545-037EF71E-D560-4AF0-921F-19630E34A1D0Q38008459-57FEA586-0626-4F28-97AC-9C252F00CF06Q38049332-F980B59F-7FB8-48A3-AABF-3ACC7E17419FQ39584788-AC1A610C-0677-417D-A507-FD75C2FC6474Q39649887-97DEF901-8FAC-43D2-96F7-ADA72DF8B9B0Q40045652-7B19DECE-A1DD-45FE-B069-46A029D4F104Q40207057-4667FE42-C7A8-4C3E-BFA7-99CA9D1891A0Q40931929-0F46548D-EF9A-4338-9AE2-7AF57B8B145FQ42228164-3D657582-F682-4EBC-B479-BE418D1C1CBDQ42273592-005C6A1C-E661-44F7-90DE-3AD466368598Q42545818-B3BE37B2-5CC4-4897-B63B-48EEAEF96060Q42643475-EC373AAA-5EBD-41A0-8905-660F8DF3B3A7Q43234796-CAF4F80A-4053-4440-897E-E4462E21505BQ43451889-350BDDB0-1BC3-4373-85D1-76FC4D39F653Q50134154-735AD395-C4D5-4366-B1DA-91F5CD243929Q57179932-F63812BA-0A60-4BD4-90A4-11BD46AB1B4AQ57543752-E12ACFA7-809D-45C0-8548-B0A361965AF4Q58589290-18D33FA8-4ED8-41A9-969C-7BC28D05648C
P2860
Therapeutic options for Acinetobacter baumannii infections.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic options for Acinetobacter baumannii infections.
@en
Therapeutic options for Acinetobacter baumannii infections.
@nl
type
label
Therapeutic options for Acinetobacter baumannii infections.
@en
Therapeutic options for Acinetobacter baumannii infections.
@nl
prefLabel
Therapeutic options for Acinetobacter baumannii infections.
@en
Therapeutic options for Acinetobacter baumannii infections.
@nl
P2860
P356
P1476
Therapeutic options for Acinetobacter baumannii infections.
@en
P2093
Jerónimo Pachón
P2860
P304
P356
10.1517/14656566.9.4.587
P407
P50
P577
2008-03-01T00:00:00Z